Endpoints News
Spark vet gets $89M for startup Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T Wed Th F
15 July, 2026
Endpoints 11 - Reserve Your Spot
The most differentiated science stays out of public view. This September, the Endpoints newsroom reveals the 11 private companies worth watching, live at the State Room in Boston. See the list first, reserve your spot and save with the early bird rate.
spotlight
top stories
1. Braveheart files for IPO to fund Phase 3 of Hengrui's Cytokinetics rival
2. J&J's 'must-win launch' Icotyde nabs 18,000 prescriptions in first full quarter
3. Exclusive: Lipid nanoparticle startup Nava emerges with $89M to target T cells and kidney
4. Radiopharma maker AdvanCell hauls in $315M for Pluvicto challenger
5. Insilico, Bora Pharma reveal plans for AI-driven manufacturing company
6. I&I startup Attovia files to go public as biotech listings momentum builds
7. Veradermics declares first efficacy win in women for hair loss drug
8. Celcuity wins approval for breast cancer drug Revtorpyk
more stories
• 
Alex Hoffman
.

We are minutes away from a Post-Hoc Live featuring Executive Editor Drew Armstrong and our resident IPO expert Kyle LaHucik. They'll be speaking with Parabilis Medicines CEO Mathai Mammen and Kailera Therapeutics CEO Ron Renaud about how the IPO environment has warmed up considerably in 2026, and the timing is fortuitous: Braveheart Bio and Attovia Therapeutics just filed their paperwork. Watch here at 12 p.m. ET.
.
Alex Hoffman
Copy Chief and News Editor, Endpoints News
Braveheart CEO Travis Murdoch
1
by Kyle LaHucik

Biotechs are sprint­ing to the IPO queue.

In the in­dus­try's fourth IPO fil­ing in two weeks, Brave­heart Bio is seek­ing a Nas­daq list­ing to fu­el...

Read the full story
2
by Max Gelman

John­son & John­son teased some de­tails on Wednes­day morn­ing about how the launch of its ex­pect­ed block­buster Ico­tyde per­formed in the sec­ond quar­ter.

With­out dis­clos­ing...

Read the full story
Manufacturing Day 2026
A year into the tariff era, the biopharma industry has stopped bracing for impact — however manufacturing and supply chain leaders are still rewriting their plans on the fly. We’re bringing together the experts tracking what R&D logistics looks like today. Join us — find out what’s next.
Federico Mingozzi, Nava Therapeutics CEO
3
by Ryan Cross

Na­va Ther­a­peu­tics, a se­cre­tive start­up that’s been work­ing on a new gen­er­a­tion of lipid nanopar­ti­cles that tar­get the bone mar­row, im­mune cells and the kid­ney...

Read the full story
4
by Lei Lei Wu

Ad­van­Cell raised a $315 mil­lion Se­ries D to study a lead-based prostate can­cer agent and shore up its US man­u­fac­tur­ing of the ra­dioac­tive treat­ment.

The...

Read the full story
5
by Anna Brown

In­sil­i­co Med­i­cine and Tai­wan-based CD­MO Bo­ra Phar­ma­ceu­ti­cals are launch­ing a new com­pa­ny with an AI-dri­ven bi­o­log­ics man­u­fac­tur­ing plat­form in a bid to com­pete with ser­vice...

Read the full story
Endpoints webinars